{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Pre-existing ADA"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Treatment induced ADA"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Treatment boosted ADA"}],"denoms":[{"counts":[{"groupId":"OG000","value":"151"}],"units":"Participants"}],"description":"ADA were categorized as: pre-existing, treatment induced and treatment boosted response. Pre-existing ADA was defined as ADA that were present in samples drawn during the pretreatment period (i.e., before the first isatuximab administration). Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without preexisting ADA, including participants without pretreatment samples. Treatment boosted ADA was defined as pre-existing ADA that increased at least 2 titer steps between pre-treatment and post-treatment.","groups":[{"description":"Participants received isatuximab 10 mg/kg IV infusion on Days 1, 8, 15, and 22 at Cycle 1, and then on Days 1 and 15 of subsequent cycles plus pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle and dexamethasone 40 mg (participants \\>= 75 years of age received 20 mg dexamethasone), PO or IV on Day 1, 8, 15, 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 76.7 weeks).","id":"OG000","title":"IPd (Isatuximab + Pomalidomide + Dexamethasone)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Analysis was performed on ADA evaluable population which included participants who received at least one dose of study drug from the IPd arm with at least one ADA assessment during the ADA on-study observation period with a reportable result. Data for this OM was not planned to be collected and analyzed for Pd arm.","reportingStatus":"POSTED","timeFrame":"From randomization up to 60 days after last dose of study drug (maximum duration 76.7 weeks)","title":"Number of Participants With Anti-drug Antibodies (ADA)","type":"SECONDARY","unitOfMeasure":"Participants"}